Simulations Plus (SLP) Announces Proposed Underwritten Public Offering of Common Stock

Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

All of the shares of common stock to be sold in the offering will be offered by Simulations Plus. In addition, Simulations Plus expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock offered in the public market. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Oppenheimer & Co. Inc. and Raymond James & Associates, Inc. are acting as joint book-running managers for the offering.

Simulations Plus intends to use the net proceeds from the offering for strategic mergers and acquisitions, although Simulations Plus has no present commitments or agreements to enter into any such mergers or acquisitions, working capital requirements and other general corporate purposes, including investing in enhanced information and accounting systems, and personnel in support of corporate growth.

This offering is being made pursuant to an automatic shelf registration statement on Form S-3 (No. 333-239770), which was previously filed with the Securities and Exchange Commission (“SEC”) on July 9, 2020, which became automatically effective.

You May Also Be Interested In

• Singularity Future Technology closes $1.8M registered direct offering
• Baxter names John Rogers as CFO, effective October 2026
• Cosmos Health posts 29% revenue rise in Q2 but net loss widens